

WEST Search History

DATE: Wednesday, April 02, 2003

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
			result set
side by side			
	<i>DB=JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ</i>		
L44	wo-9747612-\$ did.	2	L44
	<i>DB=USPT,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ</i>		
L43	us-6437143-\$ did.	2	L43
	<i>DB=JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ</i>		
L42	L37 and L41	0	L42
L41	L25 and L28	4	L41
L40	L27 and L39	0	L40
L39	L28 and L29	229	L39
L38	L27 and L29	1	L38
L37	L27 and L28	36	L37
L36	L27 and L33	0	L36
L35	L27 and L32	0	L35
L34	L32 and L33	1	L34
L33	L29 and imbalance	4	L33
L32	L28 and imbalance	30	L32
L31	mammal or human or homo sapiens	202199	L31
L30	method or process or procedure or device or attempts or means or ways	8889941	L30
L29	(hormone or insulin or endocrine secret\$6) same dysfunction	419	L29
L28	Insulin	10619	L28
L27	(restore or maintain or recupe or normalize)	5286	L27
L26	diabetes or diabetic retinopathy or obesity or obese or cataract or hyperinsulinemia or hyperglycemia	28074	L26
L25	percutaneous near5 administra\$6	417	L25
	<i>DB=USPT,PGPB; PLUR=YES; OP=ADJ</i>		
L24	L22 and L23	1	L24
L23	L16 and L18	17	L23
L22	L8 and L16	6	L22
L21	L16 and L20	0	L21
L20	L6 and L19	11	L20
L19	L8 and L18	81	L19
L18	L7 and imbalance	1197	L18
L17	L15 and L16	0	L17

L16	L4 and L7	195	L16
L15	L13 and L14	12	L15
L14	L8 and imbalance	120	L14
L13	L10 and L12	66	L13
L12	L9 and L11	68	L12
L11	L6 and L8	68	L11
L10	mammal or human or homo sapiens	360774	L10
L9	method or process or procedure or device or attempts or means or ways	3077408	L9
L8	(hormone or insulin or endocrine secret\$6) same dysfunction	1169	L8
L7	Insulin	28757	L7
L6	(restore or maintain or recupe or normalize)	15143	L6
L5	diabetes or diabetic retinopathy or obesity or obese or cataract or hyperinsulinemia or hyperglycemia	34824	L5
L4	percutaneous near5 administra\$6	1594	L4
L3	L1 and L2	5	L3
L2	((514/178)!.CCLS.))	710	L2
L1	((514/909)!.CCLS.)	214	L1

END OF SEARCH HISTORY

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 4 of 4 returned.** 1. Document ID: US 20030027804 A1

L51: Entry 1 of 4

File: PGPB

Feb 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030027804

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030027804 A1

TITLE: Therapeutic combinations for the treatment of hormone deficiencies

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KMC](#) | [Draw Desc](#) | [Image](#) 2. Document ID: US 20030022877 A1

L51: Entry 2 of 4

File: PGPB

Jan 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030022877

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030022877 A1

TITLE: Method of increasing testosterone and related steroid concentrations in women[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KMC](#) | [Draw Desc](#) | [Image](#) 3. Document ID: US 20020150625 A1

L51: Entry 3 of 4

File: PGPB

Oct 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020150625

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020150625 A1

TITLE: Topical testosterone formulations and associated methods[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KMC](#) | [Draw Desc](#) | [Image](#) 4. Document ID: US 20020061869 A1

L51: Entry 4 of 4

File: PGPB

May 23, 2002

PGPUB-DOCUMENT-NUMBER: 20020061869

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020061869 A1

TITLE: Free insulin testosterone test

Case Creation Option

Case "09898770M" already exists. Please overwrite it or cancel the operation.

The Contents of Case "09898770M"

Qnum	Query	DB Name	Thesaurus	Operator	Plural
Q1	((514/909)!.CCLS.)	USPT,PGPB	None	ADJ	YES
Q2	((514/178)!.CCLS.))	USPT,PGPB	None	ADJ	YES
Q3	Q1 and Q2	USPT,PGPB	None	ADJ	YES
Q4	percutaneous near5 administra\$6	USPT,PGPB	None	ADJ	YES
Q5	diabetes or diabetic retinopathy or obesity or obese or cataract or hyperinsulinemia or hyperglycemia	USPT,PGPB	None	ADJ	YES
Q6	(restore or maintain or recupe or normalize)	USPT,PGPB	None	ADJ	YES
Q7	Insulin	USPT,PGPB	None	ADJ	YES
Q8	(hormone or insulin or endocrine secret\$6) same dysfunction	USPT,PGPB	None	ADJ	YES
Q9	method or process or procedure or device or attempts or means or ways	USPT,PGPB	None	ADJ	YES
Q10	mammal or human or homo sapiens	USPT,PGPB	None	ADJ	YES
Q11	Q6 and Q8	USPT,PGPB	None	ADJ	YES
Q12	Q9 and Q11	USPT,PGPB	None	ADJ	YES
Q13	Q10 and Q12	USPT,PGPB	None	ADJ	YES
Q14	Q8 and imbalance	USPT,PGPB	None	ADJ	YES
Q15	Q13 and Q14	USPT,PGPB	None	ADJ	YES
Q16	Q4 and Q7	USPT,PGPB	None	ADJ	YES
Q17	Q15 and Q16	USPT,PGPB	None	ADJ	YES
Q18	Q7 and imbalance	USPT,PGPB	None	ADJ	YES

Q19	Q8 and Q18	USPT,PGPB	None	ADJ	YES
Q20	Q6 and Q19	USPT,PGPB	None	ADJ	YES
Q21	Q16 and Q20	USPT,PGPB	None	ADJ	YES
Q22	Q8 and Q16	USPT,PGPB	None	ADJ	YES
Q23	Q16 and Q18	USPT,PGPB	None	ADJ	YES
Q24	Q22 and Q23	USPT,PGPB	None	ADJ	YES
Q25	percutaneous near 5 administra\$6	JPAB,EPAB,DWPI	None	ADJ	YES
Q26	diabetes or diabetic retinopathy or obesity or obese or cataract or hyperinsulinemia or hyperglycemia	JPAB,EPAB,DWPI	None	ADJ	YES
Q27	(restore or maintain or recupe or normalize)	JPAB,EPAB,DWPI	None	ADJ	YES
Q28	Insulin	JPAB,EPAB,DWPI	None	ADJ	YES
Q29	(hormone or insulin or endocrine secret\$6) same dysfunction	JPAB,EPAB,DWPI	None	ADJ	YES
Q30	method or process or procedure or device or attempts or means or ways	JPAB,EPAB,DWPI	None	ADJ	YES
Q31	mammal or human or homo sapiens	JPAB,EPAB,DWPI	None	ADJ	YES
Q32	Q28 and imbalance	JPAB,EPAB,DWPI	None	ADJ	YES
Q33	Q29 and imbalance	JPAB,EPAB,DWPI	None	ADJ	YES
Q34	Q32 and Q33	JPAB,EPAB,DWPI	None	ADJ	YES
Q35	Q27 and Q32	JPAB,EPAB,DWPI	None	ADJ	YES
Q36	Q27 and Q33	JPAB,EPAB,DWPI	None	ADJ	YES
Q37	Q27 and Q28	JPAB,EPAB,DWPI	None	ADJ	YES
Q38	Q27 and Q29	JPAB,EPAB,DWPI	None	ADJ	YES
Q39	Q28 and Q29	JPAB,EPAB,DWPI	None	ADJ	YES
Q40	Q27 and Q39	JPAB,EPAB,DWPI	None	ADJ	YES
Q41	Q25 and Q28	JPAB,EPAB,DWPI	None	ADJ	YES
Q42	Q37 and Q41	JPAB,EPAB,DWPI	None	ADJ	YES
Q43	us-6437143-\$ did.	USPT,JPAB,EPAB,DWPI	None	ADJ	YES
Q44	wo-9747612-\$ did.	JPAB,EPAB,DWPI	None	ADJ	YES

L41: Entry 2 of 4

File: DWPI

Oct 2, 2002

DERWENT-ACC-NO: 1998-076807

DERWENT-WEEK: 200273

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: New 5-phenoxy-alkyl-2,4-thiazolidine- di:ketone(s) - used to treat non-insulin dependent diabetes, are non-toxic to the liver and do not affect insulin secretion

INVENTOR: BOTTON, G; DOARE, L ; KERGOAT, M ; MESANGEAU, D ; MOINET, G ; PRUGNARD, E

PATENT-ASSIGNEE:

ASSIGNEE	CODE
MERCK PATENT GMBH	MERE
LIPHA LYONNAISE IND PHARM	LIPH
BOTTON G	BOTTI
DOARE L	DOARI
KERGOAT M	KERGI
MESANGEAU D	MESAI
MOINET G	MOINI
PRUGNARD E	PRUGI

PRIORITY-DATA: 1996FR-0007070 (June 7, 1996)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
DE 69715009 E	October 2, 2002		000	C07D277/34
WO 9747612 A1	December 18, 1997	F	043	C07D277/34
FR 2749583 A1	December 12, 1997		053	C07D277/34
ZA 9704984 A	March 25, 1998		043	C07D000/00
AU 9730317 A	January 7, 1998		000	
NO 9805671 A	December 4, 1998		000	C07D277/34
CZ 9803975 A3	March 17, 1999		000	C07D277/34
EP 918759 A1	June 2, 1999	F	000	
SK 9801645 A3	June 11, 1999		000	
CN 1221410 A	June 30, 1999		000	
BR 9709654 A	August 10, 1999		000	
NZ 333645 A	May 26, 2000		000	C07D277/34
JP 2000507270 W	June 13, 2000		078	C07D277/34
NZ 503471 A	June 23, 2000		000	C07C053/16
JP 3067809 B2	July 24, 2000		020	C07D277/34
JP 2000226379 A	August 15, 2000		018	C07D277/34
MX 9810265 A1	April 1, 1999		000	C07D277/34
AU 726549 B	November 9, 2000		000	C07D277/34
HU 200001744 A2	November 28, 2000		000	C07D277/34
KR 2000016412 A	March 25, 2000		000	C07D277/34
TW 400330 A	August 1, 2000		000	A61K031/395
US 20010007875 A1	July 12, 2001		000	C07D277/04
RU 2169144 C2	June 20, 2001		000	C07D277/34
NO 312100 B1	March 18, 2002		000	C07D277/34
CN 1341588 A	March 27, 2002		000	C07C069/734
US 6437143 B1	August 20, 2002		000	C07D277/34
EP 918759 B1	August 28, 2002	F	000	C07D277/34
IL 127408 A	August 14, 2002		000	C07D277/34

DESIGNATED-STATES: AL AM AT AU AZ BA BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE GH
 HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD
 SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AT BE CH DE DK EA ES FI FR GB GH GR IE IT
 KE LS LU MC MW NL OA PT SD SE SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT
 SE AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
DE 69715009E	June 2, 1997	1997DE-0615009	
DE 69715009E	June 2, 1997	1997EP-0925034	
DE 69715009E	June 2, 1997	1997WO-EP02851	
DE 69715009E		EP 918759	Based on
DE 69715009E		WO 9747612	Based on
WO 9747612A1	June 2, 1997	1997WO-EP02851	
FR 2749583A1	June 7, 1996	1996FR-0007070	
ZA 9704984A	June 5, 1997	1997ZA-0004984	
AU 9730317A	June 2, 1997	1997AU-0030317	
AU 9730317A		WO 9747612	Based on
NO 9805671A	June 2, 1997	1997WO-EP02851	
NO 9805671A	December 4, 1998	1998NO-0005671	
CZ 9803975A3	June 2, 1997	1997WO-EP02851	
CZ 9803975A3	June 2, 1997	1998CZ-0003975	
CZ 9803975A3		WO 9747612	Based on
EP 918759A1	June 2, 1997	1997EP-0925034	
EP 918759A1	June 2, 1997	1997WO-EP02851	
EP 918759A1		WO 9747612	Based on
SK 9801645A3	June 2, 1997	1997WO-EP02851	

SK 9801645A3	June 2, 1997	1998SK-0001645	
CN 1221410A	June 2, 1997	1997CN-0195320	
BR 9709654A	June 2, 1997	1997BR-0009654	
BR 9709654A	June 2, 1997	1997WO-EP02851	
BR 9709654A		WO 9747612	Based on
NZ 333645A	June 2, 1997	1997NZ-0333645	
NZ 333645A	June 2, 1997	1997WO-EP02851	
NZ 333645A		WO 9747612	Based on
JP2000507270W	June 2, 1997	1997WO-EP02851	
JP2000507270W	June 2, 1997	1998JP-0501140	
JP2000507270W		WO 9747612	Based on
NZ 503471A	June 2, 1997	1997NZ-0333645	Div ex
NZ 503471A	June 2, 1997	1997NZ-0503471	
NZ 503471A		NZ 333645	Div ex
JP 3067809B2	June 2, 1997	1997WO-EP02851	
JP 3067809B2	June 2, 1997	1998JP-0501140	
JP 3067809B2		JP 200007270	Previous Publ.
JP 3067809B2		WO 9747612	Based on
JP2000226379A	June 2, 1997	1998JP-0501140	Div ex
JP2000226379A	June 2, 1997	1999JP-0355996	
MX 9810265A1	December 4, 1998	1998MX-0010265	
AU 726549B	June 2, 1997	1997AU-0030317	
AU 726549B		AU 9730317	Previous Publ.
AU 726549B		WO 9747612	Based on
HU 200001744A2	June 2, 1997	1997WO-EP02851	
HU 200001744A2	June 2, 1997	2000HU-0001744	
HU 200001744A2		WO 9747612	Based on
KR2000016412A	June 2, 1997	1997WO-EP02851	
KR2000016412A	December 7, 1998	1998KR-0709995	
KR2000016412A		WO 9747612	Based on
TW 400330A	June 6, 1997	1997TW-0107848	
US20010007875A1	June 2, 1997	1997WO-EP02851	
US20010007875A1	December 7, 1998	1998US-0202076	
RU 2169144C2	June 2, 1997	1997WO-EP02851	
RU 2169144C2	June 2, 1997	1999RU-0100100	
RU 2169144C2		WO 9747612	Based on
NO 312100B1	June 2, 1997	1997WO-EP02851	
NO 312100B1	December 4, 1998	1998NO-0005671	
NO 312100B1		NO 9805671	Previous Publ.
CN 1341588A	June 2, 1997	1997CN-0195320	Div ex
CN 1341588A	June 2, 1997	2001CN-0103050	
US 6437143B1	June 2, 1997	1997WO-EP02851	
US 6437143B1	December 7, 1998	1998US-0202076	
US 6437143B1		WO 9747612	Based on
EP 918759B1	June 2, 1997	1997EP-0925034	
EP 918759B1	June 2, 1997	1997WO-EP02851	
EP 918759B1		WO 9747612	Based on
IL 127408A	June 2, 1997	1997IL-0127408	
IL 127408A		WO 9747612	Based on

A , MX 9810265 A1 INT-CL (IPC): A61K 31/395; A61K 31/425; A61K 31/426; A61K 31/427; A61P 3/10; A61P 5/50; A61P 9/12; A61P 31/10; A61P 39/02; A61P 39/06; C07C 53/16; C07C 53/23; C07C 55/02; C07C 69/62; C07C 69/63; C07C 69/635; C07C 69/734; C07D 0/00; C07D 277/04; C07D 277/12; C07D 277/34; C07D 277/40; C07D 417/12

ABSTRACTED-PUB-NO: EP 918759B

BASIC-ABSTRACT:

5-Phenoxyalkyl-2,4-thiazolidine diones of formula (I), their tautomers, enantiomers, diastereomers, epimers, solvates with water or organic solvents, and salts, are new. A = 2-16C alkylene; D = mono-, bi-, or tri-cyclic, homo- or hetero-carbonaceous, aromatic structure including one or more heteroatoms; X = H, 1-6C alkyl, 1-6C alkoxy, 1-6C alkoxy(1-6C alkyl), aryl, optionally substituted aryl(1-6C alkyl), aryl(1-6C alkyl)aryl, halo, CF₃, cyano, hydroxy, nitro, amino, carboxyl, alkoxy carbonyl, carboxamide, sulphonyl, sulphone, sulphonamide, sulphamoyl, alkylsulphonyl-amino, acylamino, or trifluoromethoxy; aryl = one or two ring aromatic structure, optionally with one or two heteroatoms in the ring; n = 1-3; with the restriction that when A = butyl, (X)_nD is not 4-chlorophenyl. Also claimed are new intermediates formed during the synthesis of (I), of formulae (VII), (VIII), (IX), (XIII), (XV) and (XVII). Hal = Cl or Br; R₁, R₁' = alkyl; B = 1-15C alkylene; B' = 1-14C alkylene; and R' = alkyl, aryl or aralkyl (optionally substituted).

USE - Pharmaceutical use for parenteral, digestive, rectal, permucosal, and percutaneous administration is claimed. (I) can be used to treat non-insulinopaenic diabetes, with hypo- and hyper-insulinism. (I) improve control of glycaemia and reduce circulating insulin. Prevention of relative hyperinsulinism associated with improvement in dyslipidaemia and antioxidant activity, leads to reduced risks of micro- and macro-angiopathy. (I) can be used in the treatment of metabolic insulin-resistance syndrome. (I) can be used to treat hypertension in insulin-resistant subjects, associated or not with other metabolic anomalies. Some (I) have diuretic activity and anti-hypertensive activity (diminution of Ca²⁺ capture observed in rat aorta). In addition some have antiradical activity with respect to the hydroxyl anion and superoxide.

ADVANTAGE - (I) have advantages over compounds of prior art in that they do not affect insulin secretion, they do act on insulin resistance, they are non-toxic to the liver, and they can be used in the treatment of diabetes with hyperinsulinism.

ABSTRACTED-PUB-NO:

US 6437143B

EQUIVALENT-ABSTRACTS:

5-Phenoxyalkyl-2,4-thiazolidine diones of formula (I), their tautomers, enantiomers, diastereomers, epimers, solvates with water or organic solvents, and salts, are new. A = 2-16C alkylene; D = mono-, bi-, or tri-cyclic, homo- or hetero-carbonaceous, aromatic structure including one or more heteroatoms; X = H, 1-6C alkyl, 1-6C alkoxy, 1-6C alkoxy(1-6C alkyl), aryl, optionally substituted aryl(1-6C alkyl), aryl(1-6C alkyl)aryl, halo, CF₃, cyano, hydroxy, nitro, amino, carboxyl, alkoxy carbonyl, carboxamide, sulphonyl, sulphone, sulphonamide, sulphamoyl, alkylsulphonyl-amino, acylamino, or trifluoromethoxy; aryl = one or two ring aromatic structure, optionally with one or two heteroatoms in the ring; n = 1-3; with the restriction that when A = butyl, (X)_nD is not 4-chlorophenyl. Also claimed are new intermediates formed during the synthesis of (I), of formulae (VII), (VIII), (IX), (XIII), (XV) and (XVII). Hal = Cl or Br; R₁, R₁' = alkyl; B = 1-15C alkylene; B' = 1-14C alkylene; and R' = alkyl, aryl or aralkyl (optionally substituted).

USE - Pharmaceutical use for parenteral, digestive, rectal, permucosal, and percutaneous administration is claimed. (I) can be used to treat non-insulinopaenic diabetes, with hypo- and hyper-insulinism. (I) improve control of glycaemia and reduce circulating insulin. Prevention of relative hyperinsulinism associated with improvement in dyslipidaemia and antioxidant activity, leads to reduced risks of micro- and macro-angiopathy. (I) can be used in the treatment of metabolic insulin-resistance syndrome. (I) can be used to treat hypertension in insulin-resistant subjects, associated or not with other metabolic anomalies. Some (I) have diuretic activity and anti-hypertensive activity (diminution of Ca²⁺ capture observed in rat aorta). In addition some have antiradical activity with respect to the hydroxyl anion and superoxide.

ADVANTAGE - (I) have advantages over compounds of prior art in that they do not affect insulin secretion, they do act on insulin resistance, they are non-toxic to the liver, and they can be used in the treatment of diabetes with hyperinsulinism.

5-Phenoxyalkyl-2,4-thiazolidine diones of formula (I), their tautomers, enantiomers, diastereomers, epimers, solvates with water or organic solvents, and salts, are new. A = 2-16C alkylene; D = mono-, bi-, or tri-cyclic, homo- or hetero-carbonaceous,

aromatic structure including one or more heteroatoms; X = H, 1-6C alkyl, 1-6C alkoxy, 1-6C alkoxy(1-6C alkyl), aryl, optionally substituted aryl(1-6C alkyl), aryl(1-6C alkyl)aryl, halo, CF₃, cyano, hydroxy, nitro, amino, carboxyl, alkoxy carbonyl, carboxamide, sulphonyl, sulphone, sulphonamide, sulphamoyl, alkylsulphonyl-amino, acylamino, or trifluoromethoxy; aryl = one or two ring aromatic structure, optionally with one or two heteroatoms in the ring; n = 1-3; with the restriction that when A = butyl, (X)_nD is not 4-chlorophenyl. Also claimed are new intermediates formed during the synthesis of (I), of formulae (VII), (VIII), (IX), (XIII), (XV) and (XVII). Hal = Cl or Br; R₁, R_{1'} = alkyl; B = 1-15C alkylene; B' = 1-14C alkylene; and R' = alkyl, aryl or aralkyl (optionally substituted).

USE - Pharmaceutical use for parenteral, digestive, rectal, permucosal, and percutaneous administration is claimed. (I) can be used to treat non-insulinopaenic diabetes, with hypo- and hyper-insulinism. (I) improve control of glycaemia and reduce circulating insulin. Prevention of relative hyperinsulinism associated with improvement in dyslipidaemia and antioxidant activity, leads to reduced risks of micro- and macro-angiopathy. (I) can be used in the treatment of metabolic insulin-resistance syndrome. (I) can be used to treat hypertension in insulin-resistant subjects, associated or not with other metabolic anomalies. Some (I) have diuretic activity and anti-hypertensive activity (diminution of Ca²⁺ capture observed in rat aorta). In addition some have antiradical activity with respect to the hydroxyl anion and superoxide.

ADVANTAGE - (I) have advantages over compounds of prior art in that they do not affect insulin secretion, they do act on insulin resistance, they are non-toxic to the liver, and they can be used in the treatment of diabetes with hyperinsulinism.

US20010007875A

5-Phenoxyalkyl-2,4-thiazolidine diones of formula (I), their tautomers, enantiomers, diastereomers, epimers, solvates with water or organic solvents, and salts, are new. A = 2-16C alkylene; D = mono-, bi-, or tri-cyclic, homo- or hetero-carbonaceous, aromatic structure including one or more heteroatoms; X = H, 1-6C alkyl, 1-6C alkoxy, 1-6C alkoxy(1-6C alkyl), aryl, optionally substituted aryl(1-6C alkyl), aryl(1-6C alkyl)aryl, halo, CF₃, cyano, hydroxy, nitro, amino, carboxyl, alkoxy carbonyl, carboxamide, sulphonyl, sulphone, sulphonamide, sulphamoyl, alkylsulphonyl-amino, acylamino, or trifluoromethoxy; aryl = one or two ring aromatic structure, optionally with one or two heteroatoms in the ring; n = 1-3; with the restriction that when A = butyl, (X)_nD is not 4-chlorophenyl. Also claimed are new intermediates formed during the synthesis of (I), of formulae (VII), (VIII), (IX), (XIII), (XV) and (XVII). Hal = Cl or Br; R₁, R_{1'} = alkyl; B = 1-15C alkylene; B' = 1-14C alkylene; and R' = alkyl, aryl or aralkyl (optionally substituted).

USE - Pharmaceutical use for parenteral, digestive, rectal, permucosal, and percutaneous administration is claimed. (I) can be used to treat non-insulinopaenic diabetes, with hypo- and hyper-insulinism. (I) improve control of glycaemia and reduce circulating insulin. Prevention of relative hyperinsulinism associated with improvement in dyslipidaemia and antioxidant activity, leads to reduced risks of micro- and macro-angiopathy. (I) can be used in the treatment of metabolic insulin-resistance syndrome. (I) can be used to treat hypertension in insulin-resistant subjects, associated or not with other metabolic anomalies. Some (I) have diuretic activity and anti-hypertensive activity (diminution of Ca²⁺ capture observed in rat aorta). In addition some have antiradical activity with respect to the hydroxyl anion and superoxide.

ADVANTAGE - (I) have advantages over compounds of prior art in that they do not affect insulin secretion, they do act on insulin resistance, they are non-toxic to the liver, and they can be used in the treatment of diabetes with hyperinsulinism.

WO 9747612A

CHOSEN-DRAWING: Dwg.0/0

TITLE-TERMS: NEW PHENOXY ALKYL THIAZOLIDINE DI KETONE TREAT NON INSULIN DEPEND DIABETES NON TOXIC LIVER AFFECT INSULIN SECRETION

DERWENT-CLASS: B02 B03

CPI-CODES: B06-H; B07-H; B10-A08; B10-A10; B10-A15; B10-B01; B10-B02A; B10-C02; B10-C03; B10-D03; B10-E02; B10-G02; B14-F02B; B14-N08; B14-S04;

CHEMICAL-CODES:

Chemical Indexing M2 *01*

Fragmentation Code

C316 D010 D012 D020 D040 D150 F010 F012 F014 F015
F019 F020 F021 F029 F710 G001 G002 G010 G011 G012
G013 G014 G015 G016 G017 G019 G020 G021 G022 G029
G040 G100 G111 G112 G113 G221 G299 H100 H101 H121
H122 H123 H141 H142 H143 H321 H322 H323 H341 H342
H343 H401 H402 H403 H421 H422 H423 H441 H442 H443
H5 H521 H522 H523 H541 H542 H543 H581 H582 H583
H601 H602 H603 H604 H608 H609 H621 H622 H623 H641
H642 H643 H685 H689 H8 J011 J012 J013 J111 J112
J113 J131 J132 J133 J211 J212 J231 J232 J311 J312
J321 J322 J331 J332 J341 J342 J5 J522 K353 K399
L142 L143 L199 L9 L910 M111 M112 M113 M114 M115
M116 M119 M121 M122 M123 M124 M125 M126 M129 M132
M135 M139 M150 M210 M211 M212 M213 M214 M215 M216
M220 M221 M222 M223 M224 M225 M226 M231 M232 M233
M240 M262 M271 M272 M280 M281 M282 M283 M311 M312
M313 M314 M315 M316 M321 M322 M323 M331 M332 M333
M340 M342 M344 M353 M362 M373 M391 M392 M393 M412
M413 M510 M511 M521 M522 M523 M530 M531 M532 M533
M540 M630 M640 M650 M710 M800 M903 M904 P522 P526
P722 P816 Q624

Markush Compounds

199807-34505-N

Chemical Indexing M2 *02*

Fragmentation Code

C316 D010 D020 D040 F010 F019 F020 F021 F029 G001
G002 G010 G011 G012 G013 G014 G015 G016 G017 G019
G020 G021 G022 G029 G040 G100 G111 G112 G113 G221
G299 H100 H101 H121 H122 H123 H141 H142 H143 H321
H322 H323 H341 H342 H343 H401 H402 H403 H421 H422
H423 H441 H442 H443 H5 H521 H522 H523 H541 H542
H543 H581 H582 H583 H6 H600 H602 H603 H608 H609
H621 H622 H623 H641 H642 H643 H683 H685 H689 H8
J0 J012 J013 J014 J111 J112 J113 J131 J132 J133
J2 J211 J212 J231 J232 J272 J311 J312 J321 J322
J331 J332 J341 J342 K353 K399 L142 L143 L199 M111
M112 M113 M114 M115 M116 M119 M121 M122 M123 M124
M125 M126 M129 M132 M135 M139 M150 M210 M211 M212
M213 M214 M215 M216 M220 M221 M222 M223 M224 M225
M226 M231 M232 M233 M240 M262 M271 M272 M281 M282
M283 M311 M312 M313 M314 M315 M316 M321 M322 M323
M331 M332 M333 M340 M342 M344 M349 M353 M362 M373
M391 M392 M393 M412 M413 M414 M510 M511 M520 M521
M522 M523 M530 M531 M532 M533 M540 M630 M640 M650
M710 M903 M904

Markush Compounds

199807-34504-N

Chemical Indexing M2 *03*

Fragmentation Code

C316 D010 D020 D040 F010 F019 F020 F021 F029 G001
G002 G010 G011 G012 G013 G014 G015 G016 G017 G019
G020 G021 G022 G029 G040 G100 G111 G112 G113 G221
G299 H100 H101 H121 H122 H123 H141 H142 H143 H321
H322 H323 H341 H342 H343 H401 H402 H403 H421 H422
H423 H441 H442 H443 H5 H521 H522 H523 H541 H542
H543 H581 H582 H583 H6 H600 H602 H603 H608 H609

H621 H622 H623 H641 H642 H643 H682 H685 H689 H8
J0 J011 J012 J013 J014 J1 J111 J112 J113 J131
J132 J133 J171 J211 J212 J231 J232 J311 J312 J321
J322 J331 J332 J341 J342 K353 K399 L142 L143 L199
M111 M112 M113 M114 M115 M116 M119 M121 M122 M123
M124 M125 M126 M129 M132 M135 M139 M150 M210 M211
M212 M213 M214 M215 M216 M220 M221 M222 M223 M224
M225 M226 M231 M232 M233 M240 M262 M271 M272 M280
M281 M282 M283 M311 M312 M313 M314 M315 M316 M321
M322 M323 M331 M332 M333 M340 M342 M343 M344 M349
M353 M362 M373 M391 M392 M393 M412 M413 M414 M510
M511 M520 M521 M522 M523 M530 M531 M532 M533 M540
M630 M640 M650 M710 M903 M904

Markush Compounds
199807-34503-N

Chemical Indexing M2 *04*

Fragmentation Code

C316 D010 D020 D040 F010 F012 F014 F015 F019 F020
F021 F029 F710 G001 G002 G010 G011 G012 G013 G014
G015 G016 G017 G019 G020 G021 G022 G029 G040 G100
G111 G112 G113 G221 G299 H100 H101 H121 H122 H123
H141 H142 H143 H321 H322 H323 H341 H342 H343 H401
H402 H403 H404 H421 H422 H423 H441 H442 H443 H481
H521 H522 H523 H541 H542 H543 H581 H582 H583 H600
H601 H608 H609 H621 H622 H623 H641 H642 H643 H685
H689 J011 J012 J013 J111 J112 J113 J131 J132 J133
J211 J212 J231 J232 J311 J312 J321 J322 J331 J332
J341 J342 J5 J522 K353 K399 L142 L143 L199 L9
L910 M111 M112 M113 M114 M115 M116 M119 M121 M122
M123 M124 M125 M126 M129 M132 M135 M139 M150 M210
M211 M212 M213 M214 M215 M216 M220 M221 M222 M223
M224 M225 M226 M231 M232 M233 M240 M262 M271 M272
M280 M281 M282 M283 M311 M312 M313 M314 M315 M316
M321 M322 M323 M331 M332 M333 M340 M342 M343 M344
M353 M362 M373 M391 M392 M393 M412 M413 M414 M510
M521 M522 M523 M530 M531 M532 M533 M540 M630 M640
M650 M710 M903 M904

Markush Compounds
199807-34502-N

Chemical Indexing M2 *05*

Fragmentation Code

C316 D010 D020 D040 F010 F012 F014 F015 F019 F020
F021 F029 F710 G001 G002 G010 G011 G012 G013 G014
G015 G016 G017 G019 G020 G021 G022 G029 G040 G100
G111 G112 G113 G221 G299 H100 H101 H121 H122 H123
H141 H142 H143 H321 H322 H323 H341 H342 H343 H401
H402 H403 H421 H422 H423 H441 H442 H443 H521 H522
H523 H541 H542 H543 H581 H582 H583 H600 H608 H609
H621 H622 H623 H641 H642 H643 H685 H689 H7 H720
H721 J011 J012 J013 J111 J112 J113 J131 J132 J133
J211 J212 J231 J232 J311 J312 J321 J322 J331 J332
J341 J342 J5 J522 K353 K399 L142 L143 L199 L9
L910 M111 M112 M113 M114 M115 M116 M119 M121 M122
M123 M124 M125 M126 M129 M132 M135 M139 M150 M210
M211 M212 M213 M214 M215 M216 M220 M221 M222 M223
M224 M225 M226 M231 M232 M233 M240 M262 M271 M272
M280 M281 M282 M283 M311 M312 M313 M314 M315 M316
M321 M322 M323 M331 M332 M333 M340 M342 M343 M344
M353 M362 M373 M391 M392 M393 M412 M413 M414 M510
M521 M522 M523 M530 M531 M532 M533 M540 M630 M640
M650 M710 M903 M904

Markush Compounds
199807-34501-N

UNLINKED-DERWENT-REGISTRY-NUMBERS: 0235S

SECONDARY-ACC-NO:
CPI Secondary Accession Numbers: C1998-025651